| Eligibility |
Inclusion Criteria:
1. Patients with relapsed or refractory acute B-lymphoblastic leukemia who meet one of the
following criteria and are diagnosed as CD19 positive by flow cytometry or histology, with
the following provisions for the patient's prior treatment:
1. 2 or more bone marrow relapses;
2. Chemoresistance: relapse after chemotherapy and failure to achieve complete remission
(MRD >1%) with at least 1 additional course of chemotherapy;
3. Relapse after autologous or allogeneic hematopoietic stem cell transplantation: time
from transplantation to reinfusion is at least greater than 6 months;
4. Primary refractory: complete remission not achieved after two courses of standard
chemotherapy (MRD >1%); 2. Philadelphia chromosome-positive (Ph+) patients are
required to meet the following criteria: they should have received at least one
relapse or refractory treatment with a tyrosine kinase inhibitor (TKI) agent ±
chemotherapy or be intolerant of relapse or refractory to treatment with a TKI analog
± chemotherapy; Ph+ acute lymphoblastic leukemia (ALL) known to be accompanied by a
T315I mutation, in the absence of an effective treatment with a TKI analog, is not
require patients to be treated with TKI analogs ± chemotherapy; 3. Patients must have
evaluable evidence of disease (bone marrow morphology suggestive of =5% primitive
naive cells or bone marrow MRD >1%); 4. Age 3-70, including boundary values; 5.
Expected survival of 3 months or more; 6. Eastern Cooperative Oncology Group (ECOG)
score of 0-1 for patients aged 16 years and older (refer to Attachment 1); Lansky
score of >50 for patients under 16 years of age (refer to Attachment 2); 7. Women of
childbearing potential who have a negative blood pregnancy test prior to the start of
the trial and who agree to use effective contraception for the duration of the trial
until the last follow-up visit; male subjects whose partners are of childbearing
potential agree to use effective contraception for the duration of the trial until the
last follow-up visit; 8. Blood cell analysis meet the requirement 9. Adequate organ
function 10. Toxicity due to prior therapy has stabilized or recovered to = grade 1 or
is not considered clinically significant by the investigator; 11. Volunteer to
participate in this trial and sign on the informed consent
Exclusion Criteria:
1. Isolated extramedullary disease relapse;
2. Leukemia patients with symptoms of significant central nervous system invasion and
requiring targeted therapy;
3. Prior treatment with a gene product;
4. Plasmapheresis with symptoms of compression (e.g., pleural effusion, abdominal
effusion);
5. Patients with cardiac involvement and gastrointestinal involvement;
6. Autoimmune disease requiring systemic immunosuppressive therapy (e.g., Crohn's
disease, rheumatoid arthritis, systemic lupus) within 2 years prior to the start of
screening;
7. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina
pectoris, active arrhythmia, or other clinically significant cardiac disease within 6
months prior to the start of screening; patients with NYHA scores greater than Class I
(or is it Class II);
8. Patients with a history of symptomatic deep vein thrombosis or pulmonary embolism
within 6 months prior to the start of screening; or requiring long-term antiplatelet
therapy; or undergoing anticoagulation therapy;
9. Allergy to the study drug and related ingredients (e.g., albumin);
10. Those with Graft-versus-host disease (GVHD) requiring immunosuppression; or GVHD =
grade 2 or on anti-GVHD therapy; use of any medication for the treatment of GVHD
within 4 weeks prior to enrollment; or autoimmune disease;
11. Provisions for prior medication:
1. Systemic therapy (including chemotherapy, TKI inhibitors, and belintuzumab) 1
week or 5 half-lives prior to the cell collection period; clofarabine or
cladribine within 3 months prior to enrollment, or pembrolizumab within 3 weeks
prior to enrollment;
2. Those who have combined systemic steroid medications within 5 days prior to the
cell collection period (except those who have recently or are currently using
topical or inhaled steroids);
3. Those who have used drugs to stimulate bone marrow hematopoietic cell production
within 5 days prior to the cell collection period;
4. Patients who have participated in another clinical study within 1 month prior to
screening; or who are scheduled to participate in a clinical trial of another
drug during this study; however, enrollment will be allowed if the treatment is
ineffective or the disease has progressed during the trial and at least 5
half-lives have elapsed prior to cell collection;
5. INS19 CAR-T cells have received allogeneic cell therapy, such as donor lymphocyte
transfusion, within 6 weeks prior to transfusion;
6. Prior CAR-T cell therapy;
7. Prior treatment with anti-CD19 target (unless CD19 target test remains positive);
8. If immunotherapy such as anti-PD1, PD-L1, etc. has been used prior to INS19 CAR-T
cell infusion, at least 4 weeks must have elapsed after the last dose and prior
to INS19 CAR-T cell infusion;
9. Live vaccination within 6 weeks prior to the start of screening. ii;
12. Prior or clinically significant CNS disorders at screening, such as epilepsy,
epileptic seizures, paralysis, aphasia, stroke, severe brain injury, dementia,
Parkinson's disease, cerebellar disorders, organic brain syndromes, or psychiatric
disorders;
13. Patients has HBV, HCV, HIV ,EBV, CMV or syphilis infection at the time of screening;
14. Pregnant or lactating, or planning pregnancy within 180 days after the end of CAR-T
cells infusion, or male patients whose partners plan pregnancy 180 days after their
CAR-T cell infusion;
15. History of malignancy other than non-melanotic skin cancer or carcinoma in situ (e.g.,
cervix, bladder, breast) (unless in a disease-free state for at least 5 years);
16. Infections (fungal, bacterial, viral, or other) that require intravenous antimicrobial
control or are uncontrollable, for simple urinary tract infections, and for bacterial
pharyngitis, if the investigator assesses that they can be controlled by curative
treatment, are eligible for enrollment.
17. Comorbid hereditary bone marrow failure-related syndromes such as Fanconi anemia,
Kostmann syndrome, Schwachman syndrome, or other bone marrow failure syndromes, except
Down syndrome;
18. The presence of any factors affecting compliance with the protocol, or the
unwillingness or inability of the subject to comply with the procedures required in
the study protocol, as judged by the investigator.
|
